Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 219050, held by Caplin. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 219050 (Ephedrine Sulfate), held by Caplin, was first approved by FDA on Jul 18, 2024, with 0 approved supplements and 0 published complete response letters.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 18, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters